Skip to content

Predicting Treatment Response to Exposure Therapy Using Carbon Dioxide

Predicting Treatment Response to Exposure Therapy Using a CO2 Habituation Paradigm in Patients With High Levels of Anxiety Sensitivity

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03925987
Enrollment
70
Registered
2019-04-24
Start date
2018-06-07
Completion date
2020-07-31
Last updated
2023-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Agoraphobia, Generalized Anxiety Disorder, Panic Disorder, Social Anxiety Disorder

Brief summary

Anxiety disorders affect over a quarter of the population, yet very little is known about the variables that predict treatment outcome. The planned study explores whether a patient's response to a physiological test involving inhalation of carbon dioxide predicts their response to exposure therapy.

Detailed description

Anxiety Sensitivity (AS) refers to an individual's fear of experiencing anxiety-related symptoms (e.g., dyspnea or heart palpitations) and is a core construct underlying the initiation and maintenance of pathological anxiety. Recent evidence suggests that reducing AS may be critical for the prevention and treatment of anxiety across diagnostic categories. Exposure therapy, an important component of cognitive behavioral therapy (CBT), is one of the most effective treatments for reducing AS, and has been shown to improve symptoms across a number of different anxiety disorders. Meta-analyses reveal an approximately 50% treatment response rate, with the remaining half of patients showing either no response or dropping out of treatment early. Unfortunately, there is a paucity of research exploring which variables predict treatment outcome and there are currently no tests for predicting which patients would benefit the most from exposure therapy. In this study, participants will complete two sessions of a carbon dioxide (CO2) habituation paradigm, a safe and noninvasive physiological test that entails repeated exposures to single vital capacity inhalations of 20% CO2. Both CO2 testing sessions will be completed within a 72-hour time period. Patients then complete a 10-week group-based exposure therapy to determine whether an individual's degree of habituation to CO2 predicts treatment outcome.

Interventions

BEHAVIORALExposure therapy

10 weekly sessions of group-based exposure therapy

Sponsors

Laureate Institute for Brain Research, Inc.
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

1. DSM-V diagnosis of an Anxiety disorder (Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Agoraphobia) 2. Anxiety Sensitivity Index (ASI-3) total score \> 29 3. Overall Anxiety Severity and Impairment Scale (OASIS) score \> 8 4. Between 18-55 years of age 5. Subject must be treatment-seeking and willing to enroll in the 10-week group-based Exposure Therapy

Exclusion criteria

1. Comorbid Bipolar Disorder, Schizophrenia, Anorexia or Bulimia Nervosa, or Obsessive-Compulsive Disorder 2. Current Substance Use Disorder \> moderate (within the past 6 months) 3. Currently taking a psychotropic medication 4. Currently receiving psychotherapy/counseling for anxiety 5. Currently being treated as an inpatient 6. Active suicidal ideation with intent or plan 7. History of neurological, cardiovascular or respiratory problems (e.g., asthma, severe brain injury)

Design outcomes

Primary

MeasureTime frameDescription
Between-session habituation of self-reported anxietyAcross two days of CO2 testing within a 72-hour windowMaximum anxiety rating on a 10-point rating dial (0=no anxiety to 10=most anxiety ever) during day 1 of CO2 testing minus the maximum anxiety rating during day 2 of CO2 testing

Secondary

MeasureTime frameDescription
Between-session habituation of self-reported dyspneaAcross two days of CO2 testing within a 72-hour windowDyspnea rating (difficulty breathing, shortness of breath or smothering) on a 100-point visual analogue scale (0=not at all to 100=extremely) during day 1 of CO2 testing minus the dyspnea rating during day 2 of CO2 testing
Between-session reduction in avoidance behaviorAcross two days of CO2 testing within a 72-hour windowAverage response latency (in seconds) between vital capacity breaths of CO2 during day 1 of CO2 testing minus the average response latency during day 2 of CO2 testing

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026